<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404287</url>
  </required_header>
  <id_info>
    <org_study_id>CXUO320BES04</org_study_id>
    <secondary_id>EudraCT number 2005-003666-42</secondary_id>
    <nct_id>NCT00404287</nct_id>
  </id_info>
  <brief_title>Randomized Study to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in Patients With Aortic Stenosis.</brief_title>
  <official_title>Double Blind Randomized Phase IV Clinical Trial to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in the Haemodynamic Progression of Degenerative Aortic Stenosis. The AORTICA 1 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AORTICA Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AORTICA Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atherosclerosis and aortic stenosis share inflammatory etiopathogenic characteristics in
      common. We hypothesized that statins therapy would decrease inflammatory markers
      concentrations in patients with degenerative aortic stenosis and halt the haemodynamic
      progression of the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a prospective, phase IV-III, randomized, double blinded, active controlled
      study, to evaluate the efficacy of fluvastatin on inflammatory markers in the haemodynamic
      progression of degenerative aortic stenosis. We hypothesized that statins therapy would
      decrease inflammatory markers concentrations in patients with degenerative aortic stenosis
      and halt the haemodynamic progression of the disease. Eligible patients with degenerative
      aortic stenosis will be randomized 1:1 to fluvastatin 80 mg once daily or placebo. The
      treatment should be continued until the study end (12 months). Follow up investigations will
      be performed after 3 months and at the end of the study (12 months).
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Funding not enough to complete the study
  </why_stopped>
  <start_date type="Actual">October 1, 2006</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Actual">November 1, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To study changes in CRP (mg/dL) concentration at the end of the study (12 months)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study changes in other inflammatory biomarkers (specify in the protocol) at the end of the study (12 months)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study changes in these biomarkers in the different grades of aortic stenosis at the end of the study (12 months)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study changes change in aortic valve area and medium aortic transvalvular gradient at the end of the study (12 months)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the safety and tolerability of fluvastatin in patients with aortic stenosis.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>fluvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fluvastatin 80 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvastatin</intervention_name>
    <arm_group_label>fluvastatin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Asymptomatic

          3. Aortic stenosis defined as aortic valve leaflet thickening with reduced systolic
             opening (maximum aortic jet velocity &gt;2 m/s)

          4. Written informed consent to participate in the study

          5. Patients capable to follow all conditions along the study.

        Exclusion Criteria:

          1. Symptomatic patients caused by aortic stenosis.

          2. Patients on statins anytime in the year before inclusion.

          3. Patients diagnosed of dyslipidemia requiring statins.

          4. Temperature ³37,8 ºC in the week before inclusion.

          5. Any cardiovascular event succeeding in the three months before inclusion

          6. Known thyrotoxicosis

          7. Renal failure requiring hemodialysis

          8. Any inflammatory noncardiac diseases or other reasons known to influence the study
             biomarkers concentrations.

          9. Any surgery succeeding in the three months before inclusion.

         10. Patients with any hepatopathy that in the view of the investigator prohibits
             participation in the study.

         11. Patients with known muscular disease.

         12. Patients with any severe medical condition that in the view of the investigator
             prohibits participation in the study

         13. Use of corticoids, immunosuppressors or non steroid drugs.

         14. Any known sensitivity to study drug (fluvastatin) or class of study drug.

         15. Patients participating in any study in the last year.

         16. Women of childbearing potential not using the contraception method(s) specified in
             this study, suspicion of pregnancy, as well as women who are breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro L Sanchez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Gregorio Marañón de Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Candido Martin-Luengo, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario de Salamanca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Sanchez PL, Mazzone A. C-reactive protein in degenerative aortic valve stenosis. Cardiovasc Ultrasound. 2006 Jun 14;4:24. Review.</citation>
    <PMID>16774687</PMID>
  </reference>
  <reference>
    <citation>Sánchez PL, Santos JL, Kaski JC, Cruz I, Arribas A, Villacorta E, Cascon M, Palacios IF, Martin-Luengo C; Grupo AORTICA (Grupo de Estudio de la Estenosis Aórtica). Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am J Cardiol. 2006 Jan 1;97(1):90-3. Epub 2005 Nov 10.</citation>
    <PMID>16377290</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2006</study_first_submitted>
  <study_first_submitted_qc>November 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2006</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AORTICA Group</investigator_affiliation>
    <investigator_full_name>Pedro L Sanchez</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>C reactive protein</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Aortic valve stenosis</keyword>
  <keyword>progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

